Xeris Biopharma Holdings, Inc. has filed patent infringement lawsuits against several companies, a move that could have significant implications for its KEVEYIS product.
The company filed the lawsuits on October 13, 2026, through its subsidiary, Xeris Pharmaceuticals, Inc. The filings were made in the United States District Court for the District of New Jersey against Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Limited, Lemed Pharmacy III, LLC, Lemed Specialty Pharmacy Arizona, LLC, Rising Pharma Holdings, Inc., and Rising Pharma Specialties Pvt. Ltd.
This filing is crucial for investors and consumers as it highlights Xeris's efforts to protect its intellectual property and maintain its market position for KEVEYIS, a medication used to treat certain medical conditions.
Background on Xeris Biopharma Holdings
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company based in Chicago, Illinois, that specializes in developing and commercializing innovative therapies for patients with chronic diseases. The company focuses on enhancing the delivery of medications to improve patient outcomes. The recent patent infringement lawsuits are part of its strategy to safeguard its products and intellectual property.
The filing type is an 8-K, which is used by publicly traded companies to report major events that shareholders should know about. The Accession Number for this filing is 0001867096-26-000091.
What the Filing Says
The filing states, "On October 13, 2026, Xeris Biopharma Holdings, Inc. ... filed patent infringement lawsuits ... against defendants ... in two separate actions." It further explains that these lawsuits follow the grant of U.S. Patent No. 12,758,502 related to the Company’s KEVEYIS product.
The complaints allege that the defendants will infringe the '502 patent by making, using, selling, offering for sale, and/or importing their generic dichlorphenamide products. Xeris is seeking a judgment of infringement, injunctive relief, monetary damages, enhanced damages, attorneys' fees, and other relief as deemed appropriate by the court.
Impact of the Filing
This legal action could significantly impact the companies named in the lawsuits as they may face restrictions on their ability to produce and sell their generic versions of KEVEYIS. Additionally, the outcome of these lawsuits could affect Xeris's market share and revenue from its KEVEYIS product.
Consumers who rely on KEVEYIS for treatment may also be affected, as any legal restrictions could influence the availability and pricing of the medication in the market.
What's Next
The filing does not say what happens next. However, it is expected that the legal proceedings will unfold in the coming months, with both parties preparing their cases for court.